Accessibility Menu
Novacyt logo

Novacyt(LSE) NCYT

Market Cap£32.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-28%
5 Year-85%
1 Year+17%
1 Month+28%
£0.46
+2.01%
+0.01Today
Novacyt last closing stock price
MetricPriceDate
Last closeGBX 44.702026-08-12
Novacyt stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+20.65%GBX 37.052026-08-05
1 month+27.71%GBX 35.002026-07-13
3 month+2.05%GBX 43.802026-05-14
Year to date+26.09%GBX 35.452025-12-31
1 year+17.02%GBX 38.202025-08-12
3 year-39.59%GBX 74.002023-08-11
5 year-85%GBX 298.002021-08-13
Since inception-27.73%GBX 0.602017-11-01

Novacyt Financials at a Glance

Market Cap

£32.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£30.24M

Net Income (TTM)

-£31.17M

EPS (TTM)

-£0.32

P/E Ratio

-1.38

Dividend

£0.00

Beta (Volatility)

-0.23 (Low)

Price

£0.46

Volume

56,296

Open

£0.47

Previous Close

£0.45

Daily Range

£0.45 - £0.47

52-Week Range

£0.27 - £0.82

Estimated Earnings Date

Sep 24, 2026

NCYT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novacyt

Novacyt S.A. specializes in the research, production, and market launch of diagnostic solutions for cancer and infectious diseases. The company operates internationally, with a focus on molecular real-time qPCR testing equipment and in-vitro diagnostic devices.

Products and Services
  • Molecular real-time qPCR testing equipment for infectious diseases
  • Protein-based in-vitro diagnostic devices targeting infectious illnesses
  • PCR devices for life sciences and food testing industries
Growth Outlook
  • Revenue of £10.25 million reported in Q4 2025, showing potential recovery
  • Gross profit margin improved to 34.4% in Q4 2025
  • Strong cash position with £19.12 million in cash and equivalents as of Q4 2025
Financial Highlights
  • Trailing twelve months (TTM) revenue of £51.18 million
  • Operating income margin of -62.9% in Q4 2025, indicating operational challenges
  • Current ratio of 4.74, reflecting strong liquidity position
AI Generated • Jul 27, 2026

Industry

Biotechnology

CEO

Lyn Dafydd Rees

Headquarters

Le Vésinet, IF 78140, FR

NCYT Financials

Key Financial Metrics (TTM)

Gross Margin

49.82%

Operating Margin

-52.36%

Net Income Margin

-123.91%

Return on Equity

-96.46%

Return on Capital

-39.01%

Return on Assets

-77.41%

Earnings Yield

-72.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£32.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

72.59M

Volume

56.30K

Avg. Volume

241.21K

Financials (TTM)

Gross Profit

£13.58M

Operating Income

-£13.17M

EBITDA

-£8.21M

Operating Cash Flow

-£13.13M

Capital Expenditure

-£399.26K

Free Cash Flow

-£13.53M

Cash & ST Invst.

£19.13M

Total Debt

£10.43M

Novacyt Performance Analysis

Novacyt annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 21,040,000-77.3%
20232023-12-31GBP 10,621,000-49.5%
20242024-12-31GBP 19,630,00084.8%
20252025-12-31GBP 20,029,0002.0%
Novacyt sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-46.7%
Q22025-06-30103.8%
Q32025-09-30-48.7%
Q42025-12-31100.2%
Novacyt annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.36164.6%
20232023-12-31GBP -0.4010.0%
20242024-12-31GBP -0.5947.6%
20252025-12-31GBP -0.32-45.2%
Novacyt sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3185.3%
Q22025-06-30-83.0%
Q32025-09-30-31.1%
Q42025-12-31-91.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£10.25M

+11.6%

Gross Profit

£3.52M

+119.4%

Gross Margin

34.40%

N/A

Market Cap

£32.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£138.66K

N/A

Employees

234

N/A

Net Income

-£16.56M

+30.2%

EBITDA

-£3.85M

+77.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£19.13M

-37.2%

Total Debt

£10.43M

-12.2%

Accounts Receivable

£5.00M

+34.8%

Inventory

£2.53M

+11.6%

Long Term Debt

£9.58M

-9.8%

Short Term Debt

£1.71M

+36.1%

Return on Assets

-77.41%

N/A

Return on Invested Capital

-38.25%

N/A

Free Cash Flow

-£3.36M

-240.1%

Operating Cash Flow

-£3.28M

-647.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAR.LSareum Holdings plc
£0.25-1.96%
IHC.LInspiration Healthcare Group plc
£0.19+0.00%
RUA.LRUA Life Sciences plc
£0.26-2.22%
RENX.LRenalytix Plc
£0.04-1.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$9.77+0.00%
NOKNokia
$10.32+0.09%
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%

Questions About NCYT

What is the current price of Novacyt?

Novacyt is trading at £0.46 per share.

What is the 52-week range for Novacyt?

Over the past 52 weeks, Novacyt has traded between £0.27 and £0.82.

How much debt does Novacyt have?

As of the most recent reporting period, Novacyt reported total debt of £10.45M.

How much cash does Novacyt have on hand?

Novacyt reported £19.15M in cash and cash equivalents in its most recent financial results.

What is Novacyt’s dividend yield?

Novacyt does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.